Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 19 May 2017
At a glance
- Drugs Antithymocyte globulin (Primary) ; Ciclosporin (Primary) ; Eltrombopag (Primary)
- Indications Anaemia; Aplastic anaemia; Neutropenia; Pancytopenia; Thrombocytopenia
- Focus Adverse reactions; Therapeutic Use
- 24 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 20 Apr 2017 Primary endpoint (Rate of complete hematologic response at six months for cohort 3) has been met.
- 20 Apr 2017 Primary endpoint (Rate of complete hematologic response at six months for cohort 2) has not been met.